TCA
ROIV icon

Transcend Capital Advisors’s Roivant Sciences ROIV Stock Holding History

Transcend Capital Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,563
Closed -$187K – 719
2025
Q2 		$187K Buy
+16,563
New +$180K 0.01% 593
2025
Q1 		– Sell
-19,692
Closed -$233K – 636
2024
Q4 		$233K Sell
19,692
-2,256
-10% -$26.7K 0.02% 498
2024
Q3 		$253K Buy
+21,948
New +$250K 0.02% 513

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Transcend Capital Advisors's ROIV Position: Q3 2025 in Review

Transcend Capital Advisors sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 16,563 shares — an estimated $187K sold.

Transcend Capital Advisors first reported a position in ROIV in Q3 2024 and held it in 3 quarters. The position peaked at $253K in Q3 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Transcend Capital Advisors reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
  • Transcend Capital Advisors sold 16,563 Roivant Sciences shares in Q3 2025, an estimated $187K.
  • Transcend Capital Advisors first reported a position in Roivant Sciences in Q3 2024 and held it in 3 quarters.
  • Transcend Capital Advisors's Roivant Sciences position peaked at $253K in Q3 2024.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Transcend Capital Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.